Form 4: Neurocrine Biosciences Director, Christine A Poon, Reports Stock Option and Restricted Stock Unit Grant

Director Christine A Poon reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Summary

• On May 22, 2024, Christine A Poon, a director of Neurocrine Biosciences Inc. (NBIX), reported the acquisition of derivative securities.
• These included 2,982 non-qualified stock options with an exercise price of $139.43, vesting monthly starting June 22, 2024, and expiring on May 22, 2034.
• Poon also acquired 1,435 restricted stock units (RSUs), each representing one share of Neurocrine Biosciences common stock, vesting in full on May 22, 2025.
• Following these transactions, Poon directly owns 2,982 non-qualified stock options and 1,435 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock options and RSUs, which is a common practice for director compensation.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of stock-based compensation for a company director, common in the biotechnology industry to align management interests with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation to incentivize their directors and officers.
• The vesting schedules and exercise prices are generally aligned with industry norms to retain talent and drive long-term performance.

Stakeholder Impact

• The grant of stock options and RSUs can align the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates